Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Johann S. de Bono(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Gunther Boysen, Raquel Pérez-López(Vall d'Hebron Institut de Recerca), David Dolling(Institute of Cancer Research), Matthew Clarke(Institute of Cancer Research), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Helen Mossop, Mateus Crespo(Institute of Cancer Research), Berni Ebbs(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), Emma Hall(Institute of Cancer Research), Gemma Fowler, Susana Miranda(Royal Marsden NHS Foundation Trust), Shahneen Sandhu(The University of Melbourne), Ruth Riisnaes(Institute of Cancer Research), Mark Atkin(Institute of Cancer Research), Penny Flohr(Royal Marsden NHS Foundation Trust), Adam Sharp(Institute of Cancer Research), Núria Porta, Dan R. Robinson(University of Michigan), Daniel Nava Rodrigues(Institute of Cancer Research), Zafeiris Zafeiriou(Royal Marsden NHS Foundation Trust), Alexa Gillman, Suzanne Carreira(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research), Arul M. Chinnaiyan(Howard Hughes Medical Institute), Semini Sumanasuriya(Institute of Cancer Research)
Cited by 422
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k